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Rheumatoid arthritis (RA) is a chronic and severe autoimmune disease that affects joint tissues,
bone, and cartilage. However, the pathogenesis of RA is still unclear. Autoantibodies such as rheu-
matoid factor and anti-cyclic citrullinated peptide are useful tools for early diagnosis, monitoring
disease activity, and predicting prognosis. Recently, many groups have focused their attention on
the role of microRNAs in the pathogenesis of RA, as well as a potential biomarker to monitor RA.
In fact, the expression of some microRNAs, such as miR-146a, is upregulated in different cell types
and tissues in RA patients. MicroRNAs in RA could also be considered as possible future targets for
new therapeutic approaches.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disorder
mainly characterized by the inﬂammation of synovial tissue that
can lead to destruction of bone and cartilage, and eventual disabil-
ity [1,2]. The mechanisms involved in disease initiation and pro-
gression are still incompletely understood, as RA has a complex
component induced by several genes, that interact together with
environmental and stochastic factors [1]. In recent years, RA has of-
ten been divided into subsets according to a speciﬁc autoantibody
proﬁle, linked to the presence or absence of rheumatoid factor and
anti-cyclic citrullinated peptide (anti-CCP) antibodies [3,4]. Recent
reports show that joint destruction, cardiovascular comorbiditieschemical Societies. Published by E
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atoh), echan@uﬂ.edu (E.K.L.and other extra-articular manifestations are prominent in the sub-
set of patients positive for both rheumatoid factor and anti-CCP
antibodies [5,6]. For anti-CCP positive RA patients a series of
inﬂammatory cascades are active [1]. Eventually, this inﬂamma-
tory milieu could be transformed into a destructive action on
joints, which also leads to activated immune cells, imbalances in
the regulation of cytokines and other inﬂammatory mediators
[7,8]. In the last decade, many therapies have been developed to
target speciﬁc components of the inﬂammatory and autoimmune
response in RA. In particular, anti-TNF (inﬂiximab, etanercept, ada-
limumab), anti-IL-1 (anakinra), anti-IL-6 (tocilizumab), anti-CD20
agents (rituximab), and anti-CTLA4 (abatacept) therapies have
proved to be effective [1]. Unfortunately, the response to these
drugs is variable and the outcome cannot be predicted before start-
ing the therapy; they also are linked to increased risk for infection
and cancer [9–11].
Many investigators have focused their attention on the role of
microRNAs (miRNAs) in the immune response [12]. MiRNAs are
short (about 21 nucleotides long) non-coding RNAs that can inﬂu-
encemessenger RNA (mRNA) processing at the post-transcriptional
level. Using standard nomenclature, miRNA name is assigned to
experimentally conﬁrmed new miRNAs [13]. In particular, the
abbreviation ‘‘miR’’ refers to the mature form and this preﬁx is then
followed by a dash and a number, which follows the order of nam-
ing the RNA. For example, miR-132 was named and likely discov-
ered before miR-155. MiRNAs with the same seed sequencelsevier B.V. All rights reserved.
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annotated with an additional lower case letter, as in the case of
miR-146a and miR-146b.
1.1. Biogenesis of miRNA
As shown in Fig. 1, miRNAs are transcribed from their respec-
tive gene loci as primary miRNA (pri-miRNA). Genes encoding
miRNAs exist as single genes, gene clusters, and within introns
of other genes. The maturation of pri-miRNA starts in the nucleus,
where the enzyme Drosha and its associated protein DGCR8 pro-
cess it into a 70-nucleotide precursor miRNA (pre-miRNA)Fig. 1. Biogenesis of miRNAs and their effect on mRNA targets. See text for detailed descr
processed in the nucleus by Drosha/DGCR8, to precursor miRNA (pre-miRNA). The latter i
interaction with Ago and GW182, the mature miRNA is able to exert its translational silen
biogenesis (the ‘‘mirtron’’ formation) and selection for the miRNA⁄ strand.[14,15]. An alternative pathway for the biogenesis of a very small
subset of miRNAs known as mirtrons has also been described. In
brief, these miRNAs are encoded in short introns with hairpin-
forming potential that can be spliced into pre-miRNA using exist-
ing mRNA splicing machinery, and thus bypass the requirement
for the Drosha/DGCR8 processing step [16]. The pre-miRNA is
then exported to the cytoplasm, and is further processed by an-
other enzyme, Dicer, which is a ribonuclease III (RNAse III) en-
zyme like Drosha. At this stage, the pre-miRNA is approximately
21 nucleotides long and is a duplex, composed of a guide strand
and a passenger strand (indicated as miRNA star form, miRNA⁄).
The miRNA is now ready to be loaded onto Argonaute (Ago),iption. The primary miRNA (pri-miRNA) is transcribed from respective gene(s) and is
s transported to the cytoplasm and further processed to mature miRNA. Through the
cing function on speciﬁc mRNA target(s). Alternative pathways exist for the miRNA
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(RISC). There are four Ago proteins in mammals (Ago 1–Ago 4),
but Ago2 is the most studied for its role in the miRNA pathway
[17,18]. Depending on the thermodynamic of a given miRNA-miR-
NA⁄ duplex, its loading onto the miRNA binding pocket of Ago2
may favor recruitment and retention of one strand over the other.
The passenger strand is ejected and the Ago2-bound strand serves
as the guiding strand (also known as the anti-sense strand). The
conventional designation has miRNA as the favor guiding strand
and miRNA⁄ as the passenger strand. However, recent studies
have reported that some miRNA⁄ act as guiding strands with
interesting biological functions [19]. Thus, Ago2 protects and
maintains the stability of the bound mature miRNA for recogni-
tion of its cognate mRNA target(s), resulting in translation repres-
sion and/or degradation. The major pathway summarized in Fig. 1
provides an overview in miRNA biogenesis based on the two pro-
cessing steps requiring Drosha and Dicer, respectively. Note that a
number of miRNA have been also detected in high-throughput
sequencing of RNA species in Drosha / and Dicer / mouse
embroyonic stem cells [20]. The advance in sequencing has also
allowed the identiﬁcation of certain functional miRNAs that by-
pass the Dicer processing step [21]. The signiﬁcance of these Dro-
sha-independent or Dicer-independent small RNA in mammalian
somatic cells remains to be deﬁned in future studies. The gene
expression of miRNA is now known to be regulated like other
genes at the transcriptional level, Drosha-mediated processing
step, RNA editing of transcript, and control of decay (for recent
review, see [22]).
The key protein responsible for translation repression is
GW182, which is an 182 kDa protein rich in glycine-tryptophan
(GW) dipeptide motif [23]. Recent data show that GW182 has mul-
tiple non-overlapping GW-rich domains that bind Ago2 [24] and at
least two independent, divergent translation repression domains
[25]. GW182 and Ago proteins are localized in cytoplasmic foci
known as GW bodies (GWBs) [23,26]. Interestingly, both GW182
and Ago2 are targets for autoantibodies [18,27,28] and the ﬁrst
identiﬁcation of the cytoplasmic foci GWBs was made using hu-
man autoantibodies as probes [18]. The size and number of GWBs
are correlated to increase in RNA interference activity in cells by
either siRNA [29] or miRNA [30,31]. GWBs are also known as mam-
malian processing bodies or P bodies. It has also been reported that
the formation of these large foci can be a consequence rather than
a cause of the siRNA/miRNA activity [32].
1.2. The miRNA–mRNA interaction
For the miRNA–mRNA interaction, one important requirement
is the continuous and perfect base pairing of the miRNA seed re-
gion (nucleotides 2–7) [33]. This interaction normally lies in the
30-untranslated region (UTR) and it is required for effective repres-
sion of translation [34]. However, in some cases the miRNA–mRNA
interaction can take place at the 50-UTR, leading to enhancement in
translation [35]. A number of interesting studies have now shown
that protein coding regions can also be targeted by miRNA, leading
to translational repression and degradation [36–38]. This has some
practical consequences for investigations into the targets for spe-
ciﬁc miRNAs, since to date most algorithms or software available
do not examine sequences other than those in the 30-UTR. Another
new development is the identiﬁcation of miRNA ‘‘centered sites’’
that expand the miRNA targeting code by utilizing centered pair-
ings instead of seed sequence matches [39]. The feature of centered
site-based interaction between miRNA and mRNA target 30-UTR is
that perfect pairing in the seed region or a 30-compensatory pair-
ing, is not required, instead it contains at least 11 contiguous
nucleotides that pair to a miRNA at position 4–14 or 5–15 [39].
This work has been published recently and clearly none of theavailable software, including the popular TargetScan version 5.1
[40], is programmed to detect this type of interaction.
Another practical aspect in the analysis of miRNA–mRNA inter-
action, beyond employing bioinformatics algorithms, has to take
into consideration other important factors such as cellular context,
association of cellular RNA-binding proteins, and possibly the 3D
structure of mRNA. In fact, many known mRNA-binding proteins
modulate mRNA function in a dynamic way in order to maintain
structural and functional integrity [41]. The most common algo-
rithms, such as TargetScan, as mentioned above, do not consider
structural aspects, such as the presence of cytoplasmic mRNA-
binding proteins and the three-dimensional folding of the target
mRNAs that may block access to certain ‘‘predicted’’ miRNA bind-
ing sites. For this reason, at least two methods known as called
HITS-CLIP [42] and PAR-CLIP [43] have been developed, to directly
identify protein-RNA interactions via covalently crosslinking of na-
tive RNA-binding protein-RNA complexes, including Ago protein–
miRNA–mRNA complexes; the sequences of relevant miRNA–
mRNA interactions are then determined by deep sequencing. This
is applicable not only for in vitro, but also for in vivo experiments,
as for the validation of genome-wide interaction of miR-124a in
the mouse brain [42]. Identiﬁcation of deﬁned miRNA–mRNA
interaction remains an important focus to understand control in
gene expression. miRNA are able to induce translational repression
or mRNA degradation, and in this way they are thought to control
more than 50% of all protein-coding mammalian genes [22]. A re-
cent article describes how most miRNA-mediated regulation leads
to target mRNA degradation [44].
2. miRNAs and the immune system
MiRNAs have been found in virtually all species, and over 800
human miRNAs have been detected so far [22]. MiRNAs play an
important role in many different cellular processes, and their dys-
regulation is described in various pathologic conditions, such as
cancer. The role of miRNAs in normal immune functions is impor-
tant at different levels. It has been shown that miRNAs can control
many immune processes, including granulopoiesis, T- and B-cell
development andmaturation, antigen presentation, Toll-like recep-
tor (TLR) signaling cascade and cytokine production, immunoglob-
ulin class-switch recombination in B-cells, and T-cell receptor (TCR)
signaling [45]. Some miRNAs have shown a speciﬁc role in the reg-
ulation of normal and abnormal immune functions, like miR-125b,
miR-146a, miR-150, miR-155, miR-181a/b, and miR-223 (reviewed
in [14]). In recent years, interest inmiR-146a has increased, because
this miRNA is important in the negative regulation of acute inﬂam-
matory responses during activation of innate immunity [46].
Changes in miR-146a expression are observed in human diseases,
such as inﬂammatory and autoimmune diseases, viral infections,
sepsis, multiorgan failure, and cancer [46]. There are two known
isoforms of miR-146 in human, miR-146a and miR-146b. They are
encoded by different genes, from chromosome 5 and 10, respec-
tively [47], and they probably play different roles based on their dif-
ferential expression in tissues and cell types. As mentioned before,
the alteration in miR-146a expression is an important event in the
pathogenesis of many human diseases. This happens in particular
through post-transcriptional inhibition of speciﬁc target genes, like
IRAK1 (IL-1 receptor-associated kinase 1) and TRAF6 (tumor necro-
sis factor receptor-associated factor 6) [46,48]. With the aim to
identify the involvement of miRNAs in the regulation of the innate
immune response, previous investigators found an increase of miR-
146a in human monocyte cell line THP-1 cells, when stimulated
with lipopolysaccharide (LPS, or endotoxin) [48]. LPS is a major out-
er membrane component of Gram-negative bacteria, and a very po-
tent immunostimulatory molecule. When LPS is in contact with the
innate immune system, which is known to be the primary defense
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including TNF-a, IL-6, and IL-10 [49]. This mechanism is activated
through the NF-jB pathway, with the aim to control the growth
and dissemination of pathogens and thereby to activate the adap-
tive immune response as needed, as shown in Fig. 2A. In the case
of systemic dissemination of the infection (as in bacteremia or sep-
sis), immune cells from septic patients assume a refractory state to
further LPS challenges, and they interrupt the production of inﬂam-
matory mediators [50,51]. This phenomenon is known as ‘‘endo-
toxin tolerance’’ and it is a very important host mechanism aimed
at limiting inﬂammatory damage caused by the overactivation of
the immune system induced by continuous exposure to LPS or
other bacterial TLR ligands [51]. Our studies show that miR-146a
plays a key role in innate immunity [52,53]. In the ﬁrst report, fol-
lowing LPS stimulation of THP-1 cells, we have reported that TNF-a
production increases quickly for up to 4 h and then gradually de-
creases, as expected, whereas the miR-146a level begins to go up
at about 4 h, maintaining this overproduction for the next 24 h
[52]. LPS-tolerized cells were able to regain control of the TNF-a
production 22 h after LPS removal, and this was correlated to the
decrease in miR-146a level [52]. To rule out other players in the
complex TLR signaling pathways, the key points are that up-regula-
tion via transfection of miR-146a-mimic alone canmimic LPS prim-
ing to induce tolerance, and knockdown of miR-146a viaFig. 2. Role of miR-146a in endotoxin-induced tolerance and cross-tolerance. Pa
Lipopolysaccharide (LPS) and peptidoglycan (PGN) activate immune cells through inter
activation of the MyD88 dependent pathway, followed by the sequential recruitment of I
exported to the nucleus where it activates the expression of pro-inﬂammatory cytokines
dissemination of the infectious agent and to activate the immune response as needed.
leading to disease, as in the case of sepsis, multiorgan failure, autoimmune disease, or ca
eventual maturation to miR-146a, which targets and down-regulates IRAK1 and TRAF6
miR-146a can increase up to 100 fold greater compared to untreated control monocytes.
suppresses the expression of IRAK1 and TRAF6. In this way, the cell is able to enter a state
a schematic of the relative expression of TNF-a, IRAK1/TRAF6, and miR-146a in the LPS-in
produce TNF-a, which continues for about 4–6 h. When TNF-a production decreases, miR
between TNF-a and miR-146a, as miR-146a acts negatively on IRAK1 and TRAF6 and th
challenge, due to the high levels of miR-146a, while untolerized cells respond to the setransfection of a speciﬁc antagomir (anti-miR-146a) diminishes
LPS tolerance [52]. The overall results of this study show that
miR-146a is a critical factor in the mechanisms of endotoxin toler-
ance, as shown in Fig. 2 (panels A and B). TLR signaling is governed
by the MyD88-dependent and MyD88-independent (also known as
TRIF) pathways [54]. Interestingly, except for TLR3, all the major
TLR-signaling takes place via the MyD88-dependent pathway, with
the activation of IRAK1, IRAK2, and TRAF6 [55,56]. This leads to fur-
ther investigation of the role of miR-146a in endotoxin-induced
cross-tolerance, as it is expected that the elevated level of miR-
146a will repress IRAK1, IRAK2, and TRAF6, and thus block all TLR
signaling except, perhaps, for TLR3 [53]. LPS priming of immune
cells can result in diminished cytokine response after subsequent
stimulation with TLR2 ligands. This mechanism is known as ‘‘LPS-
induced cross-tolerance’’, which is observed in cells from patients
with sepsis [57]. We have also studied the correlation between
LPS-induced miR-146a and innate immune response in THP-1 cells,
focusing on cytokine production and TLR regulation [53]. Results
show that inﬂammatory response to some TLR (TLR2, TLR4, TLR5)
ligands are reduced with the knockdown of miR-146a targets, such
as IRAK1 and TRAF6. This validates the regulatory effect of miR-
146a on these TLRs signaling, which seems to play a crucial role
for in vitro monocyte-based endotoxin-induced cross-tolerance
[53].nel A, MyD88-dependent TLR signaling pathway is regulated by miR-146a.
action with the TLR (TLR4, TLR 2/6) complex on the cell surface. This leads to the
RAK4, IRAK1, and TRAF6, and eventual activation of NF-jB. The active NF-jB is then
, such as TNF-a and IL-1b. This pathway is normally used to control the growth and
However, if this mechanism is altered, the result is the pathological dysregulation
ncer. When NF-jB is activated, it also leads to the transcription of pri-miR146a and
through translational repression and degradation of mRNA. In the presence of LPS,
This negative feedback mechanism is induced by the high level of miR-146a, and it
of tolerance against further stimulation by LPS or many other TLR ligands. Panel B is
duced tolerance using the THP-1 cell model [52,53], in which tolerized cells quickly
-146a starts to increase. Eighteen hours post-priming, a large difference is observed
e cells become tolerized. Tolerized cells do not respond to even higher dose of LPS
cond LPS challenge with higher production of TNF-a.
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cent study of its enhanced expression in one experimental murine
model of periodontal disease [58]. The maxilla and the spleen from
Apo E-/- mice chronically infected orally with polymicrobial P. gin-
givalis/T. denticola/T. forsythiawere analyzed for miRNA expression.
The results show that miR-146a has a persistent association with
these periodontal pathogens, suggesting that it may have a modu-
lating effect on chronic periodontal infection. A number of studies
have demonstrated an association between RA and periodontal
disease [59,60]. In a recent study, the association of RA and peri-
odontal disease has been identiﬁed in the third National Health
and Nutrition Examination Survey (NHANES III), a nationally repre-
sentative cross-sectional survey of non-institutionalized civilian
population [61]. As P. gingivalis is one of the major pathogens
implicated in periodontitis, it is interesting that the presence of
antibodies to P. gingivalis is reported to be correlated with anti-
CCP antibodies in RA patients and their relatives [62]. The investi-
gators suggest that P. gingivalis can break the immune tolerance
and induce the production of anti-CCP antibodies, through a mech-
anism of post-translational citrullination of arginine residues by
the bacterial enzyme peptidyl arginine deiminase (PAD). However,
the speciﬁcity for antibodies to P. gingivalis cannot be readily dem-
onstrated as they may arise from cross-reactive antibodies to other
bacteria. Furthermore, it is known that the speciﬁcity of bacterial
PAD is largely restricted to citrullination of terminal-arginine resi-
dues which are the same as citrullinated residues as in CCP or cit-
rullinated peptides generated frommammalian PAD enzymes [63].
In any case, the increased expression of miR-146a in the experi-
mental periodontal model is intriguing, because the same miRNA
has been reported as being elevated in many RA studies (see
below).
Beside innate immunity, adaptive immune response also can be
inﬂuenced by miR-146a [64]. It has been shown that miR-146a
modulates activation-induced cell death (AICD) as an anti-apopto-
tic factor, and one target of miR-146a is the Fas-associated death
domain (FADD) [64]. Furthermore, miR-146a is able to impair the
production of AP-1 transcriptional activator protein and IL-2 in-
duced by TCR engagement, and this is another element supporting
the role of miR-146a in the modulation of adaptive immunity [64].
Another recent report shows that miR-146a is able to inﬂuence
the immune response mediated by T regulatory (Treg) cells [65]. In
fact, a deﬁciency of miR-146a in Treg cells was responsible for
breaking immunological tolerance, causing fatal IFNV-dependent
immune-mediated lesions in different organs in the miR-146a
knockout mouse model [65].
3. miRNAs in rheumatoid arthritis
RA is a chronic autoimmune disease that can severely affect
multiple joint structures and synovial membranes [66]. In some
cases, it also can be associated with extra-articular manifesta-
tions, mainly involving lung, heart and renal functions [1]. Apart
from clinical and radiological features, autoantibody detection is
also important for diagnosis, especially in the early phase of RA
[67]. In particular, anti-CCP antibodies are considered to be highly
speciﬁc for severe erosive RA, and their early identiﬁcation allows
the early diagnosis and treatment of RA patients, who experience
better outcomes [67]. Recent studies have supported an impor-
tant role for miRNAs in RA, and dysregulated miRNA expression
seems to contribute to the molecular mechanisms of the disease.
As shown in Table 1, aberrant expression of several miRNAs has
already been detected in RA, in different cell types, and these
miRNAs can regulate speciﬁc pathways, thus leading to the
inﬂammatory milieu taking place in RA [68]. In 2008, our group
reported the increased expression of some miRNAs (miR-155,
miR-146a, miR-132, and miR-16) in PBMCs from RA patients[69]. The levels of expression of TRAF6 and IRAK1, two targets
of miR-146a, were not increased in RA patients when compared
with control subjects [69]. The repression of these two targets
in THP-1 cells showed a strong reduction of TNF-a level. The con-
clusions were that miR-146a expression in PBMCs mimics that of
RA synovial tissue and ﬁbroblasts, as reported earlier [70,71].
How the up-regulation of miR-146a could be related to the per-
sistent production of inﬂammatory TNF-a in RA remains unclear.
Recently, it has been shown that miR-146a can inhibit osteo-
clastogenesis, and the administration of double-stranded miR-
146a could prevent joint destruction in a collagen-induced arthri-
tis mouse model [72]. As shown in Table 2, the same miRNA has
been reported to increase between 1.43 and 4 fold in different
cells and tissues in RA, demonstrating consensus in the elevated
miR-146a expression associated with the disease [70,71,73].
However, the elevated expression of miR-146a is not speciﬁc to
RA, as it is also reported in osteoarthritis, speciﬁcally in osteoar-
thritis cartilage after stimulation by IL-1b [74]. Moreover, miR-
146a can control knee-joint homeostasis and osteoarthritis-asso-
ciated algesia, through the reduction of the inﬂammatory re-
sponse in the cartilage and synovium [75]. The main advantage
of the detection of miR-146a in circulating PBMCs is that this
opens the possibility to test it as a biomarker to monitor during
the disease course, without the need for invasive surgical proce-
dures to obtain joint tissues and cells for miRNA analysis. As pre-
viously mentioned, genetic predisposition is one of the
contributing factors involved in RA pathogenesis. One recent
work [76] shows that speciﬁc polymorphisms in the 30-UTR of
IRAK1, one of the targets of miR-146a, leads to increased suscep-
tibility to developing RA. This observation opens the possibility to
study how miRNAs and polymorphisms in their targets can lead
to RA in speciﬁc ethnic groups and in association with environ-
mental factors.
In RA patients, since 2008, other miRNAs have been detected,
each with a speciﬁc pattern of expression and a speciﬁc role in
inﬂammatory pathways (Table 1). In particular, higher expression
of miR-155 was reported in synovial cells and tissues [71]. The in-
creased levels of miR-155 were found to be associated with the
repression of MMPs (matrix metalloproteinases) production, thus
leading to modulation of joint inﬂammation. In 2009, another re-
search group identiﬁed decreased expression levels of miR-124 in
RA synoviocytes [77]. This miRNA is involved in cell proliferation,
and these investigators showed that the transfection of miR-124
precursor led to arrest of the cell cycle. Moreover, two targets of
miR-124, CDK2 (cyclin-dependent kinase 2) and MCP-1 (monocyte
chemotactic protein-1), which are involved in the inﬂammatory
process in RA, are tightly controlled by miR-124. The results
showed that miR-124 could be an important regulator of the syno-
vial inﬂammatory milieu in RA [77]. In the same year, another
group identiﬁed a new up-regulated miRNA, miR-346, in RA ﬁbro-
blast-like synoviocytes (RA FLS) [78]. This miRNA was able to indi-
rectly regulate the release of a pro-inﬂammatory cytokine, IL-18.
MiR-346 acts through the indirect inhibition of the Bruton’s tyro-
sine kinase in LPS-activated RA FLS, which is involved in the
miR-346-related regulation of IL-18. In 2010, Fulci and colleagues
[79] published their results on miRNA analysis in RA patients. They
identiﬁed the increased expression of miR-223 in CD4+ naïve T
lymphocytes. As T lymphocytes are considered to play a role in
the pathogenesis of RA, these results suggest that miR-223 could
target T-cell response and therefore contribute to the onset of
the disease. In the same year, Stanczyk published the results of
the analysis of another miRNA, miR-203 [80]. Its upregulation in
synovial ﬁbroblasts is responsible for increased MMPs and IL-6
production, thus indicating that miR-203 plays a role as pro-
inﬂammatory and joint destructive factor in RA. A recent study also
shows that miR-363 and miR-498 are downregulated in CD4+ T
Table 1
Aberrant microRNA expression reported in rheumatoid arthritis.
Cell type miRNA Fold
change
Documented or postulated effect Refs.
PBMCs miR-146a, miR-155, miR-132,
miR-16
1.8–2.6" Prolonged TNF-a production [69]
PBMCs, synovial ﬁbroblasts miR-146a 1.43–4" Regulation of TNF-a production [69,71,86,87]





miR-155 8" Repression of MMPs production and modulation of joint
inﬂammation
[71]
Synovial tissue miR-146a, pri-miR-146a/b NR, " Regulation of TNF-a and IL-1b production [70]
RA ﬁbroblast-like synoviocytes miR-124a 6.3; Suppression of cell proliferation, CDK2 and MCP-1 protein
production
[77]
RA ﬁbroblast-like synoviocytes miR-346 >7" Indirect regulation of the pro-inﬂammatory cytokine IL-18 [78]
CD4+ naïve T lymphocytes miR-223 NR, " Role in RA pathogenesis? [79]
NR, exact fold change not reported.
Table 2
MiRNA-146a detection in blood and tissue cells from rheumatoid arthritis patients.
MiRNA-146a
Samples Increased expression (fold
change)
Ref.
RA blood cells PBMCs 2.6 [69]
plasma NR [88]
Th17 1.43 [87]





FLS, ﬁbroblast-like synoviocytes; NR, exact fold change not reported; PBMCs,
peripheral blood monocytic cells. Increased levels of miR-146a are detected also in
osteoarthritis cartilage (see text for details).
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upregulated [73].
Another important and emerging ﬁeld of study for autoimmune
diseases, including RA, is represented by epigenetics. The three
main mechanisms of epigenetic control (DNA methylation, histone
modiﬁcations, and miRNA regulation) interact in the development
of the RA-synovial ﬁbroblast phenotype [81]. RA synoviocytes
show epigenetic abnormalities, mainly represented by DNA
hypomethylation and histone hyperacetylation, thus leading to
synovial proliferation [82]. In RA, synovial cells histone deacety-
lases overexpression has been demonstrated at the transcriptional
level, and the use of histone deacetylase small-interfering RNA has
revealed that this enzyme plays an important role in the synovio-
cyte proliferation and apoptosis [83]. Another study showed that
synoviocyte hyperacetylation was associated with an increase of
histone acetyl transferases, without variation of the histone
deacetylases [84]. DNA hypomethylation is another epigenetic
modiﬁcation that can occur in RA, leading to the up-regulation of
genes coding for growth factors, receptors, adhesion molecules,
and other components responsible for the inﬂammatory milieu
and active phenotype of RA-SFs [85]. These observations show that
epigenetic control is deﬁcient in RA joint cells, suggesting that
broader analysis is required to better understand the role of these
mechanisms in the pathogenesis of RA, the identiﬁcation of epige-
netic biomarkers, and the development of speciﬁc therapies target-
ing key molecules of the epigenetic process.
4. Concluding remarks
In recent years, the study of miRNAs has become very important
due to their role as major regulators of gene expression affecting
single or multiple physiological and pathological pathways.Whether this holds true for every miRNA will need to await more
extensive analyses. Most studies focus their attention on the mech-
anisms through which a speciﬁc miRNA can inﬂuence cell growth
and differentiation, cytokine production, or other processes. These
results have clariﬁed many aspects linked to various miRNA struc-
tures and functioning, but more data are needed as there are still
many limitations to clarifying the complete functions for many
miRNAs. One problem is that differences in experimental design
can favor one mode of repression over another. To further under-
stand the role of miRNAs in disease, it is important to have
in vivo studies using mouse models. For example, as speciﬁc miR-
NA knockout mice are becoming available [65], we can have new
insights on the role of these miRNAs affecting the disease state.
Moreover, different miRNAs are up- or down-regulated, according
to the cell type analyzed, and most studies on RA are based on tis-
sue sample analysis. It would be useful to improve the method of
miRNA detection in serum or plasma in order to ﬁnd a possible cor-
relation between miRNA expression and disease activity. This
could lead to the use of miRNAs as new diagnostic and therapeutic
targets, especially using promoters or inhibitors of speciﬁc miRNAs
that are involved in RA inﬂammatory pathways. To date, miR-146a
appears to be a key player in RA, and its elevated expression is re-
lated to a speciﬁc pattern of cytokine expression, so it has become
one of the most important miRNAs for future studies in RA, but
studies of other relevant miRNAs and their mechanisms involved
in RA pathogenesis and disease expression are still needed.
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